Diabetes as a vascular disease. Dyslipidemia as a target.
Diabetes mellitus is a disorder involving multiple metabolic abnormalities that significantly increase risk of coronary heart disease (CHD). Although most typically associated with dysregulated glucose, diabetes also leads to dyslipidemia, often characterized by elevated triglyceride levels, low highdensity lipoprotein cholesterol levels, and a preponderance of small, dense low-density lipoprotein particles. Subgroup analyses of long-term studies show that therapy with 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (ie, "statins") significantly reduces risk of major CHD events in patients with diabetes as well as those with impaired fasting glucose.
Plutzky
Jorge
J
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. jplutzky@rics.bwh.harvard.edu
D000328:Adult; D050197:Atherosclerosis / Q000188:drug therapy / Q000209:etiology; D003327:Coronary Disease / Q000209:etiology*; D048909:Diabetes Complications; D050171:Dyslipidemias / Q000209:etiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008875:Middle Aged
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors